GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xcell Therapeutics Inc (XKRX:373110) » Definitions » EBITDA Margin %

Xcell Therapeutics (XKRX:373110) EBITDA Margin % : -638.21% (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Xcell Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Xcell Therapeutics's EBITDA for the three months ended in Mar. 2025 was ₩-2,105 Mil. Xcell Therapeutics's Revenue for the three months ended in Mar. 2025 was ₩330 Mil. Therefore, Xcell Therapeutics's EBITDA margin for the quarter that ended in Mar. 2025 was -638.21%.


Xcell Therapeutics EBITDA Margin % Historical Data

The historical data trend for Xcell Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcell Therapeutics EBITDA Margin % Chart

Xcell Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
Get a 7-Day Free Trial -1,594.82 -398.72 -669.27 -683.27 -407.70

Xcell Therapeutics Quarterly Data
Dec19 Dec20 Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -355.79 -361.26 -497.73 -424.65 -638.21

Competitive Comparison of Xcell Therapeutics's EBITDA Margin %

For the Biotechnology subindustry, Xcell Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xcell Therapeutics's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xcell Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Xcell Therapeutics's EBITDA Margin % falls into.


;
;

Xcell Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Xcell Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-7886.271/1934.344
=-407.70 %

Xcell Therapeutics's EBITDA Margin % for the quarter that ended in Mar. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=-2104.704/329.78
=-638.21 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Xcell Therapeutics  (XKRX:373110) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Xcell Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Xcell Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Xcell Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
333, Yeongdong-daero, Gangnam-gu, Seoul, KOR, 06188
Xcell Therapeutics Inc operates as a research company engaged in development of regenerative medicines. The company is developing proliferation media for various animal cell types.

Xcell Therapeutics Headlines

No Headlines